Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does VALACYCLOVIR Cause Malignant neoplasm progression? 13 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 13 reports of Malignant neoplasm progression have been filed in association with VALACYCLOVIR (Valacyclovir Hydrochloride). This represents 0.1% of all adverse event reports for VALACYCLOVIR.

13
Reports of Malignant neoplasm progression with VALACYCLOVIR
0.1%
of all VALACYCLOVIR reports
6
Deaths
6
Hospitalizations

How Dangerous Is Malignant neoplasm progression From VALACYCLOVIR?

Of the 13 reports, 6 (46.2%) resulted in death, 6 (46.2%) required hospitalization.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for VALACYCLOVIR. However, 13 reports have been filed with the FAERS database.

What Other Side Effects Does VALACYCLOVIR Cause?

Acute kidney injury (978) Drug ineffective (894) Off label use (593) Pyrexia (551) Drug reaction with eosinophilia and systemic symptoms (496) Confusional state (456) Rash (423) Nausea (415) Neurotoxicity (404) Altered state of consciousness (395)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which VALACYCLOVIR Alternatives Have Lower Malignant neoplasm progression Risk?

VALACYCLOVIR vs VALBENAZINE VALACYCLOVIR vs VALBENAZINE DITOSYLATE VALACYCLOVIR vs VALDECOXIB VALACYCLOVIR vs VALERIAN VALACYCLOVIR vs VALGANCICLOVIR

Related Pages

VALACYCLOVIR Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression VALACYCLOVIR Demographics